The annual meeting of the American Association for Cancer Research (AACR) is an event we at Biotech Strategy Blog really enjoy writing about due to the outstanding depth and breadth of the scientific content.
The 2021 organizers led by program committee chair Prof Charles Swanton FRS are to be congratulated in putting together a meeting that has something for everyone involved with cancer research, whether you’re in academia, industry, or clinical practice.
While we may miss the personal contact of real life meetings there are many advantages to the virtual format, including the avoidance of scheduling conflicts, the ease of hearing and seeing presentations without worrying about the person in front or poor room audio quality, not to mention the ability to stop and rewind a presentation if you didn’t quite catch what was said. The virtual format definitely improves accessibility for those who are disabled or for whom English may be a second or third language.
When the world moves on to hybrid virtual/live meetings as looks likely in 2022 then we hope we won’t lose all the advantages of the virtual meeting concept. It’s outside the scope of BSB, but there is an opportunity to reimagine the medical/scientific meeting rather than simply go back to what we had before.
Spring flowers herald the start of a new cancer conference season
In this preview post we’re taking a look at the “on-demand” sessions available starting on April 9, 2021 – we’ve selected fifteen presentations which caught our attention. Some are by researchers we’ve interviewed on BSB, others are stories we’ve been following around a particular topic or target.
If you’re looking to go outside your own area of interest at AACR21 and are overwhelmed with choice then this post offers a few suggestions and explains why they should be worth watching.
To learn more about the hot topics at AACR21 and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
George Martin’s quote seems rather apt this morning as NextCure announced there was disappointing single agent activity with their Siglec–15 directed agent (NC318) in an ongoing phase 1/2 trial.
There were a couple of initial partial responses reported at SITC last year and now it may seem as if the wheels are falling off the wagon.
What can we learn from the latest update?
It turns out quite a bit…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from recent events, subscribers can log-in or you can click to gain access to BSB Premium Content.
Some of the upcoming coming small biotechs caught our attention and may turn out to be future stars
National Harbor – There were quite a few gems in the poster halls and oral presentations from up and coming small cap biotechs at the Society for Immunotherapy of Cancer (SITC) meeting this year.
Who were they and what did we learn from them?
In the latest part of our latest SITC coverage we highlight 13 presentations – 11 from small biotechs and 2 academic abstracts – that caught our attention, explain what’s intriguing about them and why they matter.
There’s not a single big Pharma included (unless as a reference point or given in combination) since the focus is mainly on up and coming companies with their novel approaches.
The list is quite selective and not at all random from a list of over 850 abstracts.
So what stood out and what was special about them?
Some of the selections are likely hidden sleepers that few will be familiar with… they also cover a wide range of approaches, targets, different modalities and even strategic intent.
Even if you were at the SITC 2019 meeting, increasingly there were more business meetings taking up valuable time than sessions attended, so this is a great way to catch all the highlights for your trip report 😉
To learn more from our oncology coverage and get a heads up on our latest insights from the SITC annual meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
One of the expected highlights of the forthcoming European Society for Medical Oncology (Twitter #ESMO19) will be data for breast cancer immunotherapy.
In the first of our pre-ESMO19 previews we are taking a closer look at three breast cancer immunotherapy presentations that we think are noteworthy.
As a reminder, the abstracts are not yet available, so we’re not writing about data that’s not yet been presented, but instead are looking at why the presentations may be of scientific/medical interest, and what the questions we hope they will answer. In cancer biology as we heard from Professor Gerard Evan in a recent expert interview, it’s not about “what” happened, but “why”?
We have “boots on the ground” in Barcelona from Sept 27th to October 1st providing daily posts for BSB subscribers with our unique blend of data, analysis and commentary.
Do download the ESMO19 app if you want to check out what already looks like it will be a busy, informative and interesting congress in Barcelona. Hopefully the rain that struck the recent World Lung meeting in Barcelona will have gone away, leaving us with a sunny and dry spell one normally associates with Spain!
To learn more from our latest oncology conference insights and get a heads up on our latest ESMO Preview, subscribers can log-in or you can click to gain access to BSB Premium Content.
We’re continuing our mini-series on cracking the ‘glyco-code’ with an interview with Dr Lieping Chen (Yale), one of the world’s leading cancer immunologists, someone who has taken basic science and translated it into a spin-off company, NextCure (NASDAQ: NXTC) and a new product (NC318) targeting Siglec-15 that’s already being evaluated in the clinic.
Will upregulation of Siglec-15 turn out to be key in some cancer patients?
What happens if you identify a novel target that is expressed in a subset of patients that’s key to resetting the immune response and overcoming the immuno-suppressive tumor microenvironment (TME)?
Not only that, but you can potentially use a biomarker to select the patients most likely to benefit from what we’re calling a ‘targeted immunotherapy’ that’s directed at overcoming a specific immune dysfunction or defect.
Think of it as like when you press the factory re-set button on your iPad or iPhone.
Over the course of the coming year, we expect to hear a lot more about the early clinical data for this novel approach so in this expert interview we’re talking to the founder about the science that’s propelling NextCure forward.
To learn more from out latest oncology expert interview and get a heads up on their candid perspectives, subscribers can log-in or you can click to gain access to BSB Premium Content.